The long-range goal of this Program Project is to develop viral vector-based gene transfer strategies for treating genetic and acquired cardiopulmonary disorders. To this end, a group of investigators with diverse, yet complementary, interdisciplinary interests and expertise has established an integrated research effort that is underscored by a common interest in practical applications of gene therapy using recombinant AAV [rAAV). A major focus of the Program is the development of improved methods for gene transfer using recombinant AAV (rAAV) vectors. Project 1 (Muzyczka) will focus on the basic biology of AAV viral entry and intracellular trafficking. Physical, biochemical and genetic approaches will be used to identify sites on the capsid involved in co-receptor attachment, the capsid structural changes that occur during cell entry and the cellular proteins that interact with the capsid. This will complement work proposed in Projects 2 and 3 which will focus on specific pulmonary and cardiac applications and Core B (Zolotukhin), which will develop capsid libraries that will be screened for heart and lung tropism. Along with the vector development components, there is a major emphasis on solving practical issues related to gene therapy for diseases of the heart and muscle. Project 2 (Flotte) focuses on genetic disorders of fatty acid oxidation (FAO) whose deficiency results in cardiac and skeletal myopathy. This project has made progress in correction of these defects in animal models and will focus on preclinical experiments for the correction of VLCAD and MCAD as well as preclinical toxicology studies of muscle delivery for these defects using AAV8 and AAV9 vectors. Project 3 (Byrne) will focus on a deficiency in the lysosomal enzyme, acid alpha-glucosidase (GAA). This enzyme deficiency leads to glycogen accumulation in lysosomes of striated muscle, and in the infantile form, heart failure within the first year of life. Project 3 will focus on the development of the AAV9 serotype which has been successful in correcting the cardiac deficiency. Experiments will address the mechanism of AAV9 persistence, the mechanism of transduction in relation to cardiac and neuronal cells, and rAAV2/9-mediated transduction and toxicology in non-human primates. To assist the projects, the Program has established a Vector Core Laboratory (Core B, Zolotukhin), a Pathology Core (Core C, Campbell-Thompson) and an Imaging Core (Core D, Walters). The Vector Core will supply vectors of uniform and reproducible quality to all subprojects, and investigate the use of capsid libraries to develop new viral tropisms. The Pathology Core (Core C) will carry out biodistribution and toxicology studies for all subprojects. The Imaging Core will provide MRI/MRS and optical imaging support for in vivo experiments. Finally, an Administrative Core (Core A) will insure centralized fiscal management and oversight for the subprojects. The Cores will also serve as a mechanism to insure rapid exchange of information among all subprojects.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL059412-15
Application #
8300890
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Skarlatos, Sonia
Project Start
1997-09-30
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2012
Total Cost
$2,015,232
Indirect Cost
$512,351
Name
University of Florida
Department
Genetics
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Drouin, Lauren M; Lins, Bridget; Janssen, Maria et al. (2016) Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging. J Virol 90:8542-51
Doerfler, Phillip A; Todd, Adrian G; Clément, Nathalie et al. (2016) Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Hum Gene Ther 27:43-59
Todd, Adrian G; McElroy, Jessica A; Grange, Robert W et al. (2015) Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease. Ann Neurol 78:222-34
Falk, Darin J; Soustek, Meghan S; Todd, Adrian Gary et al. (2015) Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol Ther Methods Clin Dev 2:15007
Gruntman, Alisha M; Flotte, Terence R (2015) Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency. Hum Gene Ther Methods 26:77-81
Falk, Darin J; Todd, Adrian Gary; Lee, Sooyeon et al. (2015) Peripheral nerve and neuromuscular junction pathology in Pompe disease. Hum Mol Genet 24:625-36
Corti, Manuela; Smith, Barbara K; Falk, Darin J et al. (2015) Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction. Muscle Nerve 51:877-83
Elmallah, Mai K; Falk, Darin J; Nayak, Sushrusha et al. (2014) Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther 22:702-12
Corti, M; Elder, Me; Falk, Dj et al. (2014) B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol Ther Methods Clin Dev 1:
Forbes, S C; Bish, L T; Ye, F et al. (2014) Gene transfer of arginine kinase to skeletal muscle using adeno-associated virus. Gene Ther 21:387-92

Showing the most recent 10 out of 76 publications